Dapoxetine
| Evidence Level: L4 | Predicted Indications: 10 |
Table of Contents
Dapoxetine: From Premature Ejaculation to Migraine Disorder
One-Sentence Summary
Dapoxetine is a short-acting selective serotonin reuptake inhibitor (SSRI), originally used to treat premature ejaculation. The TxGNN model predicts it may be effective for migraine disorder, but this rests on a computational prediction and class-level SSRI literature only. Currently there are 0 clinical trials and 2 publications linked to this prediction, and neither studies dapoxetine in migraine.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Premature ejaculation (the Singapore licence records contain no approved indication text; this indication comes from the TxGNN knowledge graph) |
| Predicted New Indication | Migraine disorder |
| TxGNN Prediction Score | 99.34% |
| Evidence Level | L4 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 2 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the data compiled for this report. Based on known information, dapoxetine is a short-acting, selective serotonin reuptake inhibitor that acts on the serotonin transporter (SERT, gene SLC6A4). Its efficacy in premature ejaculation has been reported, and mechanistically it may be applicable to migraine.
Serotonergic dysregulation is implicated in migraine, and the SSRI class has been discussed for off-label use in migraine prophylaxis. However, this support is at the class level only. It has not been shown for dapoxetine itself. Dapoxetine is also designed for on-demand dosing with a very short half-life, which differs from the chronic dosing used for prophylaxis.
The high TxGNN score (0.993) is a computational prediction, not clinical evidence.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 33998993 | 2022 | Review | Current Neuropharmacology | Reviews off-label uses of SSRIs, including migraine. Class-level only, with no dapoxetine-specific migraine data. |
| 23504864 | 2013 | Cohort | Urologia | Compliance with dapoxetine therapy in premature ejaculation. Does not address migraine. |
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN13881P | Priligy Tablet 60mg | Film-coated tablet | Not recorded in the licence data |
| SIN13880P | Priligy Tablet 30mg | Film-coated tablet | Not recorded in the licence data |
Both licences are valid single-ingredient products from MENARINI - VON HEYDEN GmbH, oral route.
Safety Considerations
Please refer to the package insert for safety information.
The only interaction information in the data compiled for this report is pharmacological: dapoxetine's target is the serotonin transporter (SERT). It does not describe specific drug-drug interactions. Dapoxetine is not approved by the US FDA, though it has been authorised in several other countries.
Conclusion and Next Steps
Decision: Hold
Rationale: The migraine prediction rests on a high model score and class-level SSRI literature. No trials or dapoxetine-specific studies exist. Dapoxetine's on-demand, short half-life design also limits extrapolation to migraine prophylaxis. The package insert safety data has not been obtained, which blocks safety screening.
To proceed, the following is needed:
- Package insert warnings and contraindications from the HSA website
- Detailed mechanism of action data (e.g., from DrugBank)
- Dapoxetine-specific preclinical or clinical evidence in migraine
- Assessment of whether on-demand dosing is compatible with migraine use
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.